9 research outputs found
NEDA-3 status including cortical lesions in the comparative evaluation of natalizumab versus fingolimod efficacy in multiple sclerosis
Background: Cortical lesions (CLs) are typical of multiple sclerosis (MS) and have been recently incorporated in MS diagnostic criteria. Thus, the ‘no evidence of disease activity’ (NEDA) definition should now include CLs. The aim of this study was to evaluate the NEDA3 + CL status in natalizumab- or fingolimod-treated relapsing remitting MS (RMS) patients. Methods: Natalizumab- or fingolimod-treated RMS patients were enrolled in a 2-year longitudinal study based on clinical and magnetic resonance imaging (MRI) evaluations performed respectively biannually and annually. CLs were detected by double inversion recovery. The NEDA3 + CL condition was evaluated at baseline (T0) and at the end of the first (T1) and second (T2) year. Results: Of the 137 RMS patients included in the study, 86 were propensity-matched. At T2, the annualized relapse rate was lower on natalizumab ( p = 0.021), but the effect on white matter lesions ( p = 0.29) and the proportion of NEDA-3 patients ( p = 0.14) were similar in the two treatment arms. At T2, 11.6% natalizumab- and 62.8% fingolimod-treated patients had new CLs ( p < 0.001) and a higher proportion of natalizumab-treated patients (55.8% versus 11.6%, p < 0.001) achieved the NEDA3 + CL status (hazard ratio 5.2, p < 0.001). Conclusion: The incorporation of CLs in the NEDA-3 definition highlighted the higher efficacy of natalizumab versus fingolimod in suppressing disease activity in RMS patients
Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset
Intrathecal K free light chain synthesis in multiple sclerosis at clinical onset associates with local IgG production and improves the diagnostic value of cerebrospinal fluid examination
Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965-2018
Multiple Sclerosis Incidence and Prevalence Trends in the Province of Padua, Northeast Italy, 1965–2018
Supplementary Material 2, MSJ779951_supplementary_material_2 – Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset
<p>Supplementary Material 2, MSJ779951_supplementary_material_2 for Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset by Marco Puthenparampil, Antonio Zito, Giorgia Pantano, Lisa Federle, Erica Stropparo, Silvia Miante, Giustina De Silvestro, Mario Plebani and Paolo Gallo in Multiple Sclerosis Journal</p
Supplementary Material 3, MSJ779951_supplementary_material_3 – Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset
<p>Supplementary Material 3, MSJ779951_supplementary_material_3 for Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset by Marco Puthenparampil, Antonio Zito, Giorgia Pantano, Lisa Federle, Erica Stropparo, Silvia Miante, Giustina De Silvestro, Mario Plebani and Paolo Gallo in Multiple Sclerosis Journal</p
Supplementary Material 1, MSJ779951_supplementary_material_1 – Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset
<p>Supplementary Material 1, MSJ779951_supplementary_material_1 for Peripheral imbalanced TFH/TFR ratio correlates with intrathecal IgG synthesis in multiple sclerosis at clinical onset by Marco Puthenparampil, Antonio Zito, Giorgia Pantano, Lisa Federle, Erica Stropparo, Silvia Miante, Giustina De Silvestro, Mario Plebani and Paolo Gallo in Multiple Sclerosis Journal</p